Drug Trial Radar · NCT07146906
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Mar 26, 2026
Primary completion
Jul 12, 2030
Study completion Oct 18, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.
Conditions
- Immunoglobulin A Nephropathy (IgAN)
Interventions
zigakibartBiological
zigakibart 600 mg sc injections every second week for 104 weeks (2 years)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in mesangial IgA depositionTime frame: Baseline to Week 53 or 105
Locations
30 sites in 11 countries. Site status is shown where the registry gives one.
UC San Francisco Medical Center
San Francisco, California · Recruiting
Colorado Kidney Care Nephrology
Denver, Colorado · Recruiting
American Clinical Trials
Acworth, Georgia · Recruiting
Univ Of Iowa Hospitals And Clinics
Iowa City, Iowa · Recruiting
Inter Med Consultants
Edina, Minnesota · Recruiting
Novartis Investigative Site
Serra, Espírito Santo, Brazil · Recruiting
Novartis Investigative Site
Recife, Pernambuco, Brazil · Recruiting
Novartis Investigative Site
Natal, Rio Grande do Norte, Brazil · Recruiting
Novartis Investigative Site
Botucatu, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Shanghai, China · Recruiting
Novartis Investigative Site
Prague, Czechia · Recruiting
Novartis Investigative Site
Hanover, Germany · Recruiting
Novartis Investigative Site
Mainz, Germany · Recruiting
Novartis Investigative Site
Munich, Bavaria, Germany · Recruiting
Novartis Investigative Site
Ranica, BG, Italy · Recruiting
Novartis Investigative Site
Brescia, BS, Italy · Recruiting
Novartis Investigative Site
Pavia, PV, Italy · Recruiting
Novartis Investigative Site
Miyazaki, Japan · Recruiting
Novartis Investigative Site
Kawasaki, Kanagawa, Japan · Recruiting
Novartis Investigative Site
Lodz, Poland · Recruiting
Novartis Investigative Site
Opole, Poland · Recruiting
Novartis Investigative Site
Seoul, South Korea · Recruiting
Novartis Investigative Site
Seoul, Seoul, South Korea · Recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Seville, Spain · Recruiting
Novartis Investigative Site
Pamplona, Navarre, Spain · Recruiting
Novartis Investigative Site
Valencia, Valencia, Spain · Recruiting
Novartis Investigative Site
Kaohsiung City, Taiwan · Recruiting
Novartis Investigative Site
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.